Compile Data Set for Download or QSAR
Report error Found 69 Enz. Inhib. hit(s) with all data for entry = 50033385
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344263((+)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]he...)
Affinity DataIC50: 29nMAssay Description:Antagonist activity at NR2A transfected in oocytesMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50032651(1-[(1S,2S)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl...)
Affinity DataIC50: 74nMAssay Description:Antagonist activity at human NR2B expressed in HEK293 cells assessed as glutamate-induced changes in intracellular calcium concentrationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344250(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 230nMAssay Description:Iinhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344259(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 262nMAssay Description:Antagonist activity at human NR2B expressed in HEK293 cells assessed as glutamate-induced changes in intracellular calcium concentrationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344232(1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyra...)
Affinity DataIC50: 380nMAssay Description:Iinhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344232(1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyra...)
Affinity DataIC50: 508nMAssay Description:Antagonist activity at human NR2B expressed in HEK293 cells assessed as glutamate-induced changes in intracellular calcium concentrationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344260(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 673nMAssay Description:Antagonist activity at human NR2B expressed in HEK293 cells assessed as glutamate-induced changes in intracellular calcium concentrationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344250(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 770nMAssay Description:Antagonist activity at human NR2B expressed in HEK293 cells assessed as glutamate-induced changes in intracellular calcium concentrationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344232(1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyra...)
Affinity DataIC50: 1.89E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344250(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 1.89E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344251(N-((4'-fluoro-2'-methoxybiphenyl-3-yl)methyl)cyclo...)
Affinity DataIC50: 2.15E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344254(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.18E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344253(N-((2-(4-fluoro-2-methoxyphenyl)pyridin-4-yl)methy...)
Affinity DataIC50: 3.85E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50032651(1-[(1S,2S)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl...)
Affinity DataIC50: 4.25E+3nMAssay Description:Iinhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344257(N-benzyl-5-(4-fluoro-2-methoxyphenyl)pyridin-3-ami...)
Affinity DataIC50: 5.20E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344252(N-((6-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)methy...)
Affinity DataIC50: 6.23E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344255(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 6.67E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344259(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 7.11E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344256(3-(4-fluoro-2-methoxyphenyl)-5-(pyrrolidin-2-yl)py...)
Affinity DataIC50: 8.62E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344258(5-(4-fluoro-2-methoxyphenyl)-N-(tetrahydro-2H-pyra...)
Affinity DataIC50: 9.40E+3nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344234(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataIC50: 1.60E+4nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344264(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 1.86E+4nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344261(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 1.88E+4nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50032651(1-[(1S,2S)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344260(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344259(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344232(1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyra...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344250(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344260(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344259(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.00E+4nMAssay Description:Iinhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344260(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 2.70E+4nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344267(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataIC50: 3.30E+4nMAssay Description:Inhibition of human ERG expressed in CHOK1 cells electrophysiology studyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50032651(1-[(1S,2S)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl...)
Affinity DataKi:  4.60nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344250(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  12nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344232(1-cyclopropyl-N-((6-(4-fluoro-2-methoxyphenyl)pyra...)
Affinity DataKi:  27nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344251(N-((4'-fluoro-2'-methoxybiphenyl-3-yl)methyl)cyclo...)
Affinity DataKi:  48nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344233(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataKi:  53nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344234(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataKi:  54nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344252(N-((6-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)methy...)
Affinity DataKi:  66nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344259(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  80nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344254(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  112nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344260(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  116nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344241(N-((6-(2,3-difluorophenyl)pyrazin-2-yl)methyl)cycl...)
Affinity DataKi:  186nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344235(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataKi:  214nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344236(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataKi:  217nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344237(N-((6-(4-fluoro-2-methoxyphenyl)pyrazin-2-yl)methy...)
Affinity DataKi:  255nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344255(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  266nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344262(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  268nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344264(N-((5-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)methy...)
Affinity DataKi:  340nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Astrazeneca Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50344242(1-cyclopropyl-N-((6-(2,3-difluorophenyl)pyrazin-2-...)
Affinity DataKi:  341nMAssay Description:Displacement of [3H]CP101606 from NR2B in rat brain minus cerebellum membraneMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2011
Entry Details Article
PubMed
Displayed 1 to 50 (of 69 total ) | Next | Last >>
Jump to: